GlaxoSmithKline (GSK) has presented positive results from the phase III trial of its MenABCWY vaccine candidate at the European Society for Paediatric Infectious Diseases. The vaccine combination was administered in two doses, six months apart.
The trial evaluated the vaccine's effectiveness and safety in healthy individuals aged 10 to 25 years, finding that the vaccine candidate demonstrated non-inferiority in primary endpoints compared to two doses of Bexsero and one dose of Menveo, which are licensed meningococcal vaccines.
The vaccine candidate also showed effectiveness against a panel of 110 diverse meningococcal serogroup B invasive strains, accounting for 95% of strains circulating in the US.
If approved, the vaccine candidate could offer the broadest coverage against the most prevalent meningococcal serogroups and help simplify immunization schedules, improving vaccination coverage and reducing the overall burden of disease.